Iovance Biotherapeutics announces updated data from LN-145 study
Iovance Biotherapeutics announced updated data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and TIL therapy lifileucel in advanced melanoma. At 7.4-month median follow-up in the ongoing study of LN-145 in advanced cervical cancer, an 11% complete response rate, or CR, was seen. Furthermore, the median duration of response had not been reached. At 8.8-month median follow-up in the ongoing study of lifileucel in advanced melanoma, median duration of response had not been reached. Updated data from the ongoing innovaTIL-04 and innovaTIL-01 studies will be presented at the American Society of Clinical Oncology, or ASCO. As of May 14, data from the innovaTIL-04 study in 27 patients with recurrent, metastatic or persistent cervical cancer demonstrated an objective response rate of 44% and a disease control rate of 85%. At 7.4-month median follow-up, 10 patients maintained a response and the median DOR had not been reached. The mean patient age was 45 years and study participants had experienced a mean of 2.4 prior lines of therapy. As of May 8, results from Cohort 2 in the ongoing innovaTIL-01 study demonstrated an ORR of 38% in 66 consecutively dosed post-PD-1 patients with Stage IIIC/IV unresectable melanoma. In this study, patients had experienced a mean of 3.3 lines of prior therapy including anti-PD1 blocking antibody, and the patients had a high baseline tumor burden. The disease control rate was 80%. At 8.8-month median follow-up, median DOR had not been reached.